Avoid Warning Letters in View of the U.S. FDA’s Stated Goal – By AtoZ Compliance.

  • URL: http://bit.ly/1pyPbWG
  • Date: April 5th Tuesday
  • Listed: March 15, 2016 11:12 pm
  • Expires: This ad has expired
AtoZ logo 250X250px-googleplus


Speaker: John E. Lincoln

Key Take Away:

Learn how to minimize the chance of receiving an FDA Warning Letter, what to doing during and after an FDA compliance audit to avoid common areas for critical mistakes.


FDA Warning Letters and recent high-profile recalls indicate major cGMP training deficiencies in many companies.

Why Should You Attend:

Targeted cGMP issues. How can a company proactively minimize the chance of receiving a Warning Letter? Areas a company “must review” beforehand. What to doing during an FDA compliance audit training?

What to do immediately after the audit? What to do during the response period. Lessons learned.

Areas Covered In This Webinar:

• The U.S. FDA’s new aggressive implementation plans
• Proactive reviews of the applicable U.S. FDA / cGMP guidelines
• Key areas to focus limited resources

Learning Objectives:

• FDA Inspectional objectives
• Common areas for critical mistakes
• Recent trends and events
• The compliance audit

Who Will Benefit:

• Senior Management
• Project Leaders
• Regulatory Affairs
• Quality Systems Personnel
• Internal and Supplier Auditor Personnel
• R&D and Engineering Staff
• CAPA and P&PC Personnel



For more information, please visit http://bit.ly/1pyPbWG

Email: referrals@atozcompliance.com
Toll Free: +1- 844-414-1400
Tel: +1-516-900-5509

Ad Reference ID: 7456e9154b7fde9

Report problem

Processing your request, Please wait....

Leave a Reply